Added Value of Serum Hormone Measurements in Risk Prediction Models for Breast Cancer for Women Not Using Exogenous Hormones: Results from the EPIC Cohort.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Fortner, Renée T
Bueno de Mesquita, H Bas
Peeters, Petra H
van Gills, Carla H
Quirós, J Ramón
Travis, Ruth C
Merritt, Melissa A
MetadataShow full item record
TitleAdded Value of Serum Hormone Measurements in Risk Prediction Models for Breast Cancer for Women Not Using Exogenous Hormones: Results from the EPIC Cohort.
Published inClin Cancer Res 2017; 23(15):4181-9
PubliekssamenvattingPurpose: Circulating hormone concentrations are associated with breast cancer risk, with well-established associations for postmenopausal women. Biomarkers may represent minimally invasive measures to improve risk prediction models.Experimental Design: We evaluated improvements in discrimination gained by adding serum biomarker concentrations to risk estimates derived from risk prediction models developed by Gail and colleagues and Pfeiffer and colleagues using a nested case-control study within the EPIC cohort, including 1,217 breast cancer cases and 1,976 matched controls. Participants were pre- or postmenopausal at blood collection. Circulating sex steroids, prolactin, insulin-like growth factor (IGF) I, IGF-binding protein 3, and sex hormone-binding globulin (SHBG) were evaluated using backward elimination separately in women pre- and postmenopausal at blood collection. Improvement in discrimination was evaluated as the change in concordance statistic (C-statistic) from a modified Gail or Pfeiffer risk score alone versus models, including the biomarkers and risk score. Internal validation with bootstrapping (1,000-fold) was used to adjust for overfitting.Results: Among women postmenopausal at blood collection, estradiol, testosterone, and SHBG were selected into the prediction models. For breast cancer overall, model discrimination after including biomarkers was 5.3 percentage points higher than the modified Gail model alone, and 3.4 percentage points higher than the Pfeiffer model alone, after accounting for overfitting. Discrimination was more markedly improved for estrogen receptor-positive disease (percentage point change in C-statistic: 7.2, Gail; 4.8, Pfeiffer). We observed no improvement in discrimination among women premenopausal at blood collection.Conclusions: Integration of hormone measurements in clinical risk prediction models may represent a strategy to improve breast cancer risk stratification. Clin Cancer Res; 23(15); 4181-9. ©2017 AACR.
- Inclusion of endogenous hormone levels in risk prediction models of postmenopausal breast cancer.
- Authors: Tworoger SS, Zhang X, Eliassen AH, Qian J, Colditz GA, Willett WC, Rosner BA, Kraft P, Hankinson SE
- Issue date: 2014 Oct 1
- Endogenous sex hormones, prolactin and mammographic density in postmenopausal Norwegian women.
- Authors: Bremnes Y, Ursin G, Bjurstam N, Rinaldi S, Kaaks R, Gram IT
- Issue date: 2007 Dec 1
- Addition of a polygenic risk score, mammographic density, and endogenous hormones to existing breast cancer risk prediction models: A nested case-control study.
- Authors: Zhang X, Rice M, Tworoger SS, Rosner BA, Eliassen AH, Tamimi RM, Joshi AD, Lindstrom S, Qian J, Colditz GA, Willett WC, Kraft P, Hankinson SE
- Issue date: 2018 Sep
- Premenopausal endogenous steroid hormones and breast cancer risk: results from the Nurses' Health Study II.
- Authors: Fortner RT, Eliassen AH, Spiegelman D, Willett WC, Barbieri RL, Hankinson SE
- Issue date: 2013 Mar 6
- Physical activity and inactivity in relation to sex hormone, prolactin, and insulin-like growth factor concentrations in premenopausal women - exercise and premenopausal hormones.
- Authors: Tworoger SS, Missmer SA, Eliassen AH, Barbieri RL, Dowsett M, Hankinson SE
- Issue date: 2007 Sep